Neil K. Warma
CEO, President, Compliance Officer & DirectorMr. Neil K. Warma, M.B.A. is a Director at GenrAb, Inc. He is President, CEO & Director of Mongoose Bio, Inc. He serves as Chief Executive Officer and President of ProMIS Neurosciences, Inc. from August 1, 2024 and has been its Director since December 30, 2023 and was its Interim Chief Executive Officer and Interim President from December 30, 2023 to August 1, 2024 and served as its Independent Director since May 13, 2021 until December 30, 2023. He is Director of X-Therma, Inc. from June 2025. He serves as Compliance Officer of ProMIS Neurosciences, Inc. He serves as Business Advisory Board Member at Ridgeline Therapeutics GmbH and served as its Executive Chair until 2023. He serves as President & Director at Genexine, Inc. since May 2022 and had been its Chief Executive Officer. He has been a successful healthcare entrepreneur having founded, managed and advised numerous biotech and pharmaceutical companies across the globe. Mr. Warma was founder and from 2018 to 2019 served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Mr. Warma is the CEO/General Manager of I-Mab Biopharma U.S. Mr. Warma led the turnaround and rebuilding of the ProMIS Neurosciences cell therapy platform and oversaw its advance through clinical development in autoimmune and orphan diseases, expansion into China and its eventual merger with Acer Therapeutics. Mr. Warma serves as Special Advisor to the Board for Tvardi Therapeutics, Inc. He served as the Chief Executive Officer and President of Opexa Therapeutics, Inc. since June 16, 2008 and as its Acting Chief Financial Officer since March 2, 2016. Mr. Warma served as an Acting Chief Financial Officer and Principal Accounting Officer of Opexa Therapeutics Inc., from March 2009 to August 15, 2012 and also served as its Secretary. He served as Executive Officer of Acer Therapeutics Inc. He served as the Chief Executive Officer and President of Viron Therapeutics Inc. from 2004 to August 2007. While at Viron, Mr. Warma oversaw the launch of its first Phase II clinical study in cardiovascular disease. He joined Viron Therapeutics in July 2004 and has experience in the pharmaceutical and health industries in both Basel, Switzerland and New York City. He served for Novartis Pharmaceuticals at the corporate Headquarters in Switzerland, where he held various positions, commencing in 1992, within Novartis Pharmaceuticals, culminating in a Senior Position in Global Marketing. In addition, Mr. Warma worked on the international launch of a potential blockbuster gastrointestinal product. While at Novartis he served as Head of International Pharma Policy & Advocacy where he worked closely with all affiliates around the world on numerous issues related to drug development. In 2000, Mr. Warma co-founded MedExact USA, Inc. and served as its President. He was involved in the global strategic management of MedExact S.A. and was directly responsible for establishing and managing all operations in the U.S., including nurturing relationships with the U.S. Food and Drug Administration and eventually positioning MedExact for sale in 2003 to a large publicly traded company in France. He serves as a Director of London Economic Development Corporation. He had been a Director of Opexa Therapeutics, Inc. since September 2008. Previously, Mr. Warma was President and CEO and a member of the board of directors of Opexa Therapeutics, Inc., a publicly-traded biopharmaceutical company from 2008 to 2017. He serves on the Board of Directors of Orpheris, Inc. and is a Member of the Board of Directors of BioHouston. He is also a Member of the Advisory Board for MD Anderson’s Institute of Applied Cancer Science. He served as a Director of Viron Therapeutics, Inc. until August 2007. Mr. Warma has served as a director for Genexine Ltd., a public company and Biotechnology Innovation Organization since March 2021 and November 2020, respectively. Mr. Warma obtained an honors Bachelor of science degree specializing in neuroscience from the University of Toronto, obtained an honors degree specializing in Neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto.
Positions
- Company NameProMIS Neurosciences, Inc.Stock CodePMNPositionCEO, President, Compliance Officer & DirectorColleagues
- EWEugene W. WilliamsCo-Founder & Chairman
- NRNeil R. CashmanCo-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
- JKJohanne KaplanChief Development Officer
- LDLarry Douglas AltstielChief Medical Officer
- WWWilliam W. WymanIndependent Director
- JMJoshua Mandel-BrehmIndependent Director
